Cyclerion 10k
WebJul 17, 2024 · This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS. Detailed Description: IW-6463 tablets will be orally administered once-daily (QD) for up to 29 days Study Design Go to Resource links provided by the National Library of Medicine WebMar 22, 2024 · Cyclerion is eligible to receive up to $225 million in pre-commercial milestones and total potential future development, regulatory, and commercialization …
Cyclerion 10k
Did you know?
WebJan 26, 2024 · Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. ... risks and uncertainties include the risks listed under the heading “Risk Factors” and elsewhere in our 2024 Form 10-K filed on February 25, 2024, and our subsequent SEC filings including … WebCyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline …
WebWe are led by an accomplished team with an exceptional track record of discovering, developing, and commercializing meaningful therapies for patients while creating value … WebAll Form Types. All Years. Date Filing Description Download. 04/04/2024. 3. Initial Statement of Beneficial Ownership. 04/03/2024. 4. Statement of Changes in Beneficial Ownership.
WebJun 4, 2024 · Cyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, ... risks and uncertainties include the risks listed under the heading “Risk Factors” and elsewhere in our … WebSep 22, 2024 · Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion is advancing novel, first-in-class,...
WebDec 31, 2024 · Cyclerion Publications and Presentations; Our Pipeline. Pipeline; CY6463/MELAS; CY6463/ADv; CY6463/CIAS; Other Clinical Assets; Our Commitment; …
WebMar 22, 2024 · Cyclerion Therapeutics is a biopharmaceutical company on a mission to develop treatments for serious diseases. Cyclerion’s portfolio includes novel sGC stimulators that modulate a key node in a fundamental signaling network in both the CNS and the periphery. dataphysics oca35Web11 rows · Apr 3, 2024 · EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT. Mar 22, 2024. 10-K. Annual report which provides a comprehensive … bitser freewareWebFeb 24, 2024 · Applicable risks and uncertainties include the risks listed under the heading “Risk Factors” and elsewhere in our 2024 Form 10-K filed on February 24, 2024, and our subsequent SEC filings. bitservicedataphysics oca25WebFeb 24, 2024 · CYCLERION THERAPEUTICS, INC. Portions of the registrant’s definitive Proxy Statement, to be filed pursuant to Regulation 14A under the Securities Exchange … dataphysics oca40WebCyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and … bits eportal loginWebFeb 26, 2024 · – Proceeds to advance Cyclerion’s soluble guanylate cyclase (sGC) programs targeting breakthrough treatments for serious and orphan diseases – – Spin-off expected to be completed in early April 2024 – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Cyclerion Therapeutics, Inc. (Cyclerion) has entered into … dataphysics oca50